1. A 24‐week study to evaluate the effect of rilapladib on cognition and cerebrospinal fluid biomarkers of Alzheimer's disease. Issue 2 (29th June 2015) Authors: Maher‐Edwards, Gareth; De'Ath, Jeni; Barnett, Carly; Lavrov, Arseniy; Lockhart, Andrew Journal: Alzheimer's & dementia Issue: Volume 1:Issue 2(2015) Page Start: 131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A 24‐WEEK STUDY TO EVALUATE THE EFFECT OF RILAPLADIB ON COGNITION AND CSF MARKERS OF ALZHEIMER'S DISEASE. (1st July 2014) Authors: Maher‐Edwards, Gareth; De'Ath, Jeni; Barnett, Carly; Lavrov, Arseniy; Lockhart, Andrew Journal: Alzheimer's & dementia Issue: Volume 10:Supplement 4S(2014)Part 5 Page Start: P301 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Innovating Clinical Trials for Amyotrophic Lateral Sclerosis: Challenging the Established Order. (14th September 2021) Authors: van Eijk, Ruben P.A.; Nikolakopoulos, Stavros; Roes, Kit C.B.; Kendall, Lindsay; Han, Steve S.; Lavrov, Arseniy; Epstein, Noam; Kliest, Tessa; de Jongh, Adriaan D.; Westeneng, Henk-Jan; Al-Chalabi, Ammar; Van Damme, Philip; Hardiman, Orla; Shaw, Pamela J.; McDermott, Christopher J.; Eijkemans, Ma... Journal: Neurology Issue: Volume 97:Number 11(2021) Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Onasemnogene abeparvovec gene therapy for symptomatic infantile-onset spinal muscular atrophy type 1 (STR1VE-EU): an open-label, single-arm, multicentre, phase 3 trial. Issue 10 (October 2021) Authors: Mercuri, Eugenio; Muntoni, Francesco; Baranello, Giovanni; Masson, Riccardo; Boespflug-Tanguy, Odile; Bruno, Claudio; Corti, Stefania; Daron, Aurore; Deconinck, Nicolas; Servais, Laurent; Straub, Volker; Ouyang, Haojun; Chand, Deepa; Tauscher-Wisniewski, Sitra; Mendonca, Nuno; Lavrov, Arseniy; Se... Journal: Lancet neurology Issue: Volume 20:Issue 10(2021) Page Start: 832 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled, phase 2 trial. Issue 3 (March 2017) Authors: Meininger, Vincent; Genge, Angela; van den Berg, Leonard H; Robberecht, Wim; Ludolph, Albert; Chio, Adriano; Kim, Seung H; Leigh, P Nigel; Kiernan, Matthew C; Shefner, Jeremy M; Desnuelle, Claude; Morrison, Karen E; Petri, Susanne; Boswell, Diane; Temple, Jane; Mohindra, Rajat; Davies, Matt; Bull... Journal: Lancet neurology Issue: Volume 16:Issue 3(2017:Mar.) Page Start: 208 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis. Issue 7 (1st October 2020) Authors: Kelly, Madeline; Lavrov, Arseniy; Garcia-Gancedo, Luis; Parr, Jim; Hart, Robert; Chiwera, Theresa; Shaw, Christopher E.; Al-Chalabi, Ammar; Marsden, Rachael; Turner, Martin R.; Talbot, Kevin Journal: Amyotrophic lateral sclerosis and frontotemporal degeneration Issue: Volume 21:Issue 7/8(2020) Page Start: 563 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Using the ALSFRS-R in multicentre clinical trials for amyotrophic lateral sclerosis: potential limitations in current standard operating procedures. Issue 7 (2nd October 2022) Authors: Bakers, Jaap N.E.; de Jongh, Adriaan D.; Bunte, Tommy M.; Kendall, Lindsay; Han, Steve S.; Epstein, Noam; Lavrov, Arseniy; Beelen, Anita; Visser-Meily, Johanna M.A.; van den Berg, Leonard H.; van Eijk, Ruben P. A. Journal: Amyotrophic lateral sclerosis and frontotemporal degeneration Issue: Volume 23:Issue 7/8(2022) Page Start: 500 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗